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Abstract  
 Infants born very prematurely have a greatly increased risk of suffering permanent 
neurologic sequelae such as cerebral palsy (CP), a leading cause of physical disability in 
childhood (Doyle, Crowther, Middleton, Marrett, and Rouse, 2010; Stanley and Crowther, 
2008). The risk of developing CP increases exponentially as gestational age at birth decreases 
(Ancel, Livinec, Larroque, et al., 2006). Observational studies conducted during the 1980s and 
1990s found pre-term infants exposed in utero to magnesium sulfate (MgSo4) had decreased 
incidence of CP (Cahill, Stout, and Caughey, 2010). This paper compares data from several 
randomized trials as well as meta-analyses to determine whether a relationship exists between 
antenatal MgSo4 exposure and decreased incidence of CP.  
Defining the Problem 
 CP is defined by O'Shea (2008, pg 35), as "a disorder in posture and movement due to a 
defect in or lesion of the immature brain." This disorder results in permanent, non-progressive 
symptoms ranging from mild tremor to quadriplegia (Hayes, 2010). Sensation of the hands is 
impaired in about half of all cases and chronic pain is reported by more than 25% of adults. Up 
to 80% of affected individuals have at least some impairment of speech (Odding, Roebroeck
, 
and 
Stam, 2006). Low visual acuity is reported in almost 75% of all affected children (Odding et sl., 
2006). 50% of all children have gastrointestinal and feeding problems, and stunted growth occurs 
in 25% (Odding et al., 2006). Significant monetary costs are also associated with CP, both for 
affected persons, and society in general. A 2004 report by the United States Center for Disease 
Control and Prevention estimated lifetime costs, including medical, non-medical, and 
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productivity losses, for CP patients born in the year 2000 to reach 11.5 billion dollars (Honeycut, 
Dunlap, Chen, al Homsi, Grosse et al.,  2003).  
Background 
 CP is the most common cause of physical disability in children (Reddihough and 
Collins, 2003), affecting  approximately 3.6 per 1000 or about 1 in 246 individuals (Yeargin-
Allsopp, Doernberg, Benedict, Kirby, and Durkin,  2008). While the prevalence of CP has 
remained stable for two decades (Hankins and Speer, 2003), Crowther et al. (2010) found the 
prevalence among very premature infants (born less than 34 weeks gestation), and very low 
birthweight infants (born weighing less than 1500 grams), is rising. This rise is likely 
attributable to the a general rise in the rate of pre-term births.  
 In the United States 12.8% of births occur prematurely in 2006, up 21% from 1990, 
with infants as young as 23 weeks gestation now commonly surviving the neonatal period 
(Cahill et al., 2010; Doyle, et al., 2010). This is potentially problematic as the risk of 
developing CP is inversely related to gestational age at birth, with term infants having 0.1% 
prevalence (Cahill, et al., 2010) compared to a nearly 20% prevalence in infants born before 26 
weeks gestation; a 200 fold increase (Ancel et al., 2006). The correlation between very early 
birth and increased prevalence of CP is likely due to the over-all immaturity, putting pre-term 
infants at increased risk of neurologic insult. 
 Describing a specific etiology of CP is difficult as its origins are often multifactorial or  
unknown (Lawson and Badawi, 2003; Reddihough and Collins, 2003).  Prenatal events are 
thought to be responsible for approximately 70-75% of all cases of cerebral palsy, although it is 
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usually impossible to determine the exact nature and/or timing of the damaging event 
(Reddihough and Collins, 2003). The remaining 25-30 % of CP cases are thought to result from 
an insult to the brain during birth or the neonatal period resulting in a permanent change in 
brain structure or function (O'Shea, 2008). Neonatal events known to increase the risk of 
neurologic injury and CP include intracranial bleeding, hypoxic ischemic injury, septicemia, 
multiple gestation and others (Reddihough and Collins, 2003).  
 Like the etiology of CP, the exact mechanism of MgSo4 in providing neuroprotection 
remains unknown and may be multi-faceted. There is, however, evidence in animal studies that 
MgSo4 may augment secondary effects of neurologic injury. Research by Perlman (2006) 
found hypoxic brain injury to cause cell death in two phases. The initial insult can cause 
immediate neuronal demise, however, a secondary process also causes significant neuronal loss 
for approximately 72 hours after the initial event. In this period, two physiologic changes occur. 
Beginning 6 hours after  the injury, the cells' injured mitochondria begin to fail and cannot meet 
the metabolic needs of the cell. At the same time, neuronal cells become hyper-excitatory and 
begin to accumulate calcium, produce oxygen free radicals and excitotoxins, and form nitric 
oxide within the cells, all of which lead to cell death.  Perlman also found an increased rate of 
apoptosis (spontaneous cell death) after neurologic injury. This evidence is significant as 
Marret et al. (2007) found MgSo4 adminstration to have multiple neuroprotective roles after a 
neurologic insult in rats, pigs, and mice. These effects include decreased excitotoxin release, 
decreased apoptosis, prevention of modification of the nuclear cell membrane, and over-all 
improvement in neurologic function (Marret et al., 2007). These findings, as well as a growing 
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need to decrease neurologic sequelae in pre-term infants, have led to multiple studies of MgSo4 
in humans.  
Literature Review 
 Despite many attempts at finding therapies to reduce the rates of CP and neurologic 
injury both pre and postnatally, few have proven successful in randomized, controlled trials 
(Marret, Doyle, Crowther, and Middelton, 2007). However, several observational studies 
conducted during the 1980's and 1990's showed infants whose mothers received MgSo4, either 
as a tocolytic agent or to manage pre-eclampsia, had a markedly decreased risk of developing 
CP (Nelson and Grether, 1995; Stanley and Crowther, 2008). These finding were largely re-
affirmed in multiple prospective, randomized trials conducted from 1995-2008. Four of five 
studies conducted administered MgSo4 specifically for neuroprophylaxis, the fifth (MAGPIE) 
studied the efficacy of MgSo4 as treatment for pre-eclampsia, but also measured neurologic 
outcomes (Cahill, 2010; Marret et al., 2007). These studies are individually reviewed below.  
 The largest study, Beneficial Effects of Antenatal Magnesium Sulfate (BEAM), was 
conducted from 1997-2007 (Rouse, Hirtz, Thom, Varner, Spong, 2008). The study included 
2471 women presenting from 24.0 to 31.6 weeks gestation with advanced preterm labor or 
premature rupture of the membranes and no recent exposure to magnesium sulfate. Participants 
were randomized to receive either intravenous magnesium sulfate or masked study drug 
placebo.  Those receiving MgSo4 were given a 6 gram loading dose followed by a 2 gram/hour 
infusion (or equivalent rate for placebo). If after 12 hours, delivery did not occur and was not 
anticipated, the infusion was stopped. Standard clinical management and therapy was 
maintained for all study patients.  
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 Rouse et al., (2008), found fetal exposure to magnesium sulfate before anticipated 
preterm delivery did not reduce the combined risk of moderate or severe cerebral palsy or death 
(11.3% and 11.7%, respectively; relative risk, 0.97; 95% confidence interval [CI], 0.77 to 1.23),  
but did reduce  the rate of CP among survivors (1.9% vs. 3.5%). The risk of death did not differ 
significantly between the groups (9.5% vs. 8.5). No woman had a life-threatening event during 
the trial.  
 The PreMAG study (Marret, Marpeau, and Benichou, 2008) was conducted in France 
from 1997-2003 on women less than or equal to 33 weeks gestation. The trial enlisted 286 and 
278 women,
 
respectively, who were randomly assigned to receive a single infusion of 4 gm of
 
MgSO4 or 0.9% saline.  Pediatricians,
 
who were blinded to treatment, evaluated motor and 
cognitive
 
functions by using a questionnaire with developmental items
 
extracted from the 
Amiel-Tison and Denver scales and the
 
European Cerebral Palsy Network definition (Marret et 
al., 2008). When direct examination
 
was not possible, assessment was performed through 
parent telephone
 
interview. All assessments were completed at 24 months of age. 
 Results of the PreMag study showed a statistically significant decreases in both death or 
CP (16.1% Vs 20.2%, respectively), as well as a decrease in CP over-all (7% Vs. 10.2%, 
respectively). Also important, the PreMag study demonstrated no increase in maternal or 
pediatric mortality (Marret et al., 2008). 
  The ACTOMgSO4 trial (Crowther, Hiller, Doyle, and Haslam, 2003), was conducted 
from 1996-2000 in New Zealand and Australia and had a total of 1062 women enrolled.  All 
enrollees were less than 30 weeks gestation and expected to give birth within 24 hours.  
Participants in the experimental group received a 4g loading dose of MgSo4 followed by 
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1g/hour maintenance until birth.  Those in the control group received an equal volume of saline. 
Survivors were examined until they reached 2 years of age by pediatricians and psychologists. 
The study found pediatric mortality, defined as total number deaths prior to exam at 24 months 
of age, was reduced (13.8% from 17.1%), as well as combined death or CP (19.8% from 
24.0%), however, neither were statistically. None-the-less, findings of substantial gross motor 
dysfunction and combined death or substantial gross motor dysfunction were reduced at 
statistically significant levels (3.4% Vs. 6.6% and 17.0% Vs. 22.7 %, respectively). 
 The MAGPIE study (Altman, Carroli, Duley, Farrell, Moodley,  et al., 2002), was 
conducted from 1998 to 2001 with a total of 10,141 women enrolled. The trial was not focused 
on MgSo4 as a neuroprotective agent, but on MgSo4 as an effective treatment for pre-
eclampsia. This study enrolled women who were expected to give birth within 24 hours of 
admission. An initial dose of 4 gm MgSo4 was given initially followed by 1gm/hr drip over 24 
hours of a series of 5 gm intramuscular injections (IM) given every 4 hours. The placebo group 
received an identical volume of saline given over the same schedule. While the primary focus 
of MAGPIE was maternal health, the authors also included information on fetal 
neuroprotection for infants born at less than 34 weeks gestation (n= 805).  
 Results from the MAGPIE study neither supported nor contradicted the use of MgSo4 
for neuroprotection. Prevalence of CP in the treatment group was 3% vs. control 3%, and the 
outcome of death or CP 41.8% in the treatment group and 40.1% in the control (Altman et al., 
2002). Importantly, the MAGPIE study demonstrated no statistically significant increase in 
mortality among treated  infants.  However, treatment was associated with a 5 % increase in C-
section rate. 
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 The MagNET study (Mittendorf, Dambrosia, Pryde, Lee, Gianopoulos, 2002), 
conducted from 1995-1997  had a total enrollment of 149 women  who were between 25 and 33 
weeks gestation and in pre-term labor. The study had two arms, a tocolytic arm and a 
preventative arm. Women dilated less than 4 cm were included in the tocolytic arm and 
received either 4gm bolus of MgSo4 followed by 2-3 gm/hour maintenance or an alternative 
tocolytic. Women dilated to 4 or greater were in the preventative group and received either a 4 
gm MgSo4 bolus or saline placebo. This trial was terminated prematurely due to concerns the 
treatment group had increased mortality (N= 10, 11.8% in treatment group versus 1 or 1.2% in 
the placebo group. Increased infant mortality was only noted in the tocolytic arm, which 
required longer (unlimited) courses of treatment. This was the only study to show a statistically 
significant increase in infant mortality rates among infants treated with MgSo4. Results of all 
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Table 1-1: Rates of pediatric mortality, cerebral palsy and death or cerebral palsy in 
randomized controlled trials of antenatal magnesium sulfate therapy where fetuses were <34 
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 Several meta-analyses have also been completed to assess the efficacy and safety of 
MgSo4 prior to preterm birth. This review includes a Cochrane review, as well as three others, 
all of which analyzed the same five clinical trials using the primary outcomes of fetal or infant 
demise by 1 year of age, CP, moderate to severe CP, and a composite outcome of death or CP 
by 2 years of age. For this analysis, outcomes were sub-categorized into trials looking at 
MgSo4 specifically for neuroprotection, and MgSo4 given for other maternal indications such 
as hypertension or seizure prophylaxis. All included meta-analyses, summarized below, came 
to similar conclusions and support the use of MgSo4 for antenatal neuroprotection.  
 When all five trials are considered, using antenatal MgSo4 had no significant effect on 
the combined outcome of death or CP (RR 0.94; 95% CI 0.78-1.12) (Simhan and Himes, 2010). 
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However, for the four trials designed to specifically assess neuroprotective effects of MgSo4, 
there was a significant reduction in death or CP (RR 0.85; 95% CI 0.74-0.98). There was no 
significant effect on pediatric mortality rates in either subgroup. There was a significant 
reduction in the risk of cerebral palsy (overall RR 0.68; 95% CI 0.54-0.87; neuroprotection 
trials subgroup RR 0.71; 95% CI 0.55-0.91) and of moderate to severe CP  in the 
neuroprotection trials subgroup (RR 0.64; 95% CI 0.44-0.92). The absolute risk of CP was 3.7 
percent for fetuses exposed to MgSo4 versus 5.4 percent for unexposed fetuses, giving an 
absolute risk reduction of 1.7 percent (Simhan and Himes, 2010). There was also a reduction in 
risk of substantial gross motor dysfunction (overall RR 0.61; 95% CI 0.44-0.85; 
neuroprotection trials subgroup RR 0.60; 95% CI 0.43-0.83), but not in any other neurological 
outcome.  
 It is worth noting that there were competing outcomes noted in these analyses, 
specifically the finding of no significant effect of MgSo4 on the combined outcome of death or 
CP in the overall group of trials and in the subgroup looking exclusively at trials for 
neuroprotection. Simhan and Himes (2010), believe it is possible that the lack of statistical 
significance of the combined outcome is due to an increased risk of death in a subgroup of 
fetuses or infants, as suggested by two trials. While this finding should give providers pause, 
increased mortality has not been demonstrated in other clinical trials of MgSo4, including the 
MAGPIE trial, which had over 10,000 participants (Altman et al., 2002). It should be noted, 
too, that the combined outcome of "death or cerebral palsy" was reduced significantly when 
only trials designed specifically to assess the neuroprotective effect of magnesium sulfate were 
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analyzed (Simhan and Himes, 2010).  One factor that might be considered when weighing the 
risk and benefit of antenatal MgSo4 therapy for neuroprotection is gestational age. 
 A  meta-analysis by Cahill et al., 2010, concluded that MgSo4 can reduce the risk of 
CP, particularly in infants born at or below 32 weeks gestation. Cahill acknowledges that, while 
much data is still needed in regard to the use of MgSo4 for neuroprotection, it has been proven 
safe over decades of perinatal use and should be considered for neuroprotection in infants less 
than 32 weeks gestation, an age where the number of infants needed to treat (NNT) to prevent 
one case of CP is relatively low. Table 2-1, below,  illustrates the inverse relationship between 
the NNT with MgSo4 and gestational age at birth.  Table 2-1 also outlines a summary of 
baseline risk that an infant will develop CP based on  gestational age if no treatment were 
given.  
Table 2-1: Illustration of numbers needed to treat with MgSo4 stratified by gestational age 










Needed to treat 
22-27 14.6 8.0 6.6 15 
28-31 6.2 3.4 2.8 35 
32-36 0.7 0.4 0.3 333 
>37 0.11 0.06 0.05 2000 
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Treatment Risks 
 While three of the five original research trials, as well as the authors of all four meta-
analyses, recommend use of antenatal MgSo4 as a neuroprophylactic treatment, it is not 
without risks.  Crowther et al., (2010) found multiple adverse effects in women receiving the 
MgSo4 treatment including flushing, sweating, nausea, vomiting, headache, and tachycardia. 
All of these side-effects were temporary and resolved after treatment was ceased. Infants born 
to mothers treated with MgSo4 also risk temporary side effects such as decreased tone and poor 
feeding (Macdonald, Mullett, and Seshia, 2005). Importantly, only the MagNet study showed 
an increased risk of mortality with MgSo4 administration and that increase was only noted in 
the prophylaxis group (Mittendorf et al., 2002). Cahill (2010) also points out that there is 
inherent risk in using a therapy in which the mechanism of action is not well understood. None-
the-less, as the number of pre-term births and the prevalence of CP among premature infants 
rises, so do the potential benefits of MgSo4, particularly in infants less than 32 weeks gestation.  
Implications and Recommendations  
 As improvements in medical care and technology continue to lower fetal age of viability 
and increase the number of infants who survive severe neurologic injuries, it is urgent to find 
therapies to prevent the crippling, life-long effects of CP. While additional research is needed to 
better understand the precise ways in which MgSo4 affects the brain, the safety of MgSo4 has 
long been established in maternal-fetal medicine (Altman et al., 2002). Given the research cited 
above, as well as a recommendation by the World Health Organization, it may be appropriate 
for providers to consider MgSo4 for nueroprophylaxis on a broader scale (Lumbiganon, 2009).  
Because no widely accepted guidelines exist for neuroprotective MgSo4 therapy at this point, it 
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may be advisable to follow guidelines used in successful clinical trials. Also, because both risk 
of CP and efficacy of treatment are diminished in infants greater than 32 weeks gestation, 
MgSo4 neuroprophylaxis should only be attempted with infants less than 32 weeks.  
 As outlined in the BEAM trial (Rouse, et al., 2008), and PreMag (Crowther et al., 2003) 
a loading dose of 4 gm should be administered followed by a 1 mg/hour infusion up to 24 
hours. If labor ceases, the therapy should be stopped but may be re-started if labor resumes 
before the patient reaches 32 weeks gestation (Rouse et al., 2008). More data is needed to 
determine risks and efficacy of treatment in cases of high risk maternal conditions such as pre-
eclampsia, abruption, and others. Use of prophylactic MgSo4 in these patients should be 
avoided until further data is collected. 
Parent Education 
 Because MgSo4 is relatively new and it's physiologic mechanisms poorly understood,  
involving parents in the decision to use prophylaxis is essential. This can be complicated as  
there are few resources available to parents regarding MgSo4 neuroprophylaxis. This makes a 
private and detailed  provider consult invaluable. The consult should be performed by a 
physician familiar with current literature regarding MgSo4 neuroprophylaxis, and should be 
presented in relation to the family's specific risk factors, such as the infant's gestation and 
corresponding risk of CP.  This should be a realistic discussion of the potential benefits and 
side-effects of MgSo4 administration.  Parents should be encouraged to ask questions and 
repeat back what they understand the risks and potential benefits to be. Once the initial consult 
is completed, the parents can be referred to websites such as the March of Dimes 
http://www.marchofdimes.com/birthdefects_cerebralpalsy.html and "4 My Child" 
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http://www.cerebralpalsy.org/cerebral-palsy-causes/premature-birth/ to assist parents in 
understanding the various risk factors associated with pre-term birth, the range of disabilities 
associated with CP, as well as finding reassurances they (the parents) did not do anything to 
"cause" their child to have CP.  This is a difficult position for providers as it is important for 
parents to understand the risks to their baby, but the information needs to be provided in a way 
that does not induce panic in the parents.  
Conclusion 
 Premature birth is becoming more common with infants surviving birth at extremely 
young ages (Crowther, 2010). Many of these extremely premature infants' baseline risk of CP is 
nearly 20% with no prophylactic treatments available. Decades of MgSo4 use in obstetric care, 
as well as a preponderance of evidence gathered in the trials discussed above, have 
demonstrated the risk of MgSo4 therapy to be minimal, and side-effects reversible. This must 
be weighed against the risk for CP which can be substantial and the associated handicaps 
irreversible. Available evidence suggests neuroprophylactic MgSo4 provides a reasonable 
chance to prevent one of the most common and debilitating conditions associated with 
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